Eris Therapeutics' bank facilities affirmed/assigned IND AA/Stable/A1+ ratings.

This reflects parent Eris Lifesciences' strong operating performance, with 9MFY26 EBITDA at ~INR 850 Cr, robust 35%+ margins, and successful strategic acquisitions like the INR 1,242 Cr Biocon Biologics deal.

Net leverage improved to 2.2x, signaling financial stability.